Table I.

Characteristics of the subjects (n=96).

Characteristics	Value	Range	T2D	Controls	P-value
Age (years)	59.2±7.5	35–69	59.2±7.5	59.2±7.5	1.000
Gender (M/F)	48/48	-	-	-	-
BMI (kg/m2)	23.71±3.28	17.15–42.96	24.17±4.18	23.18±1.64	0.146
Total cholesterol (mmol/l)	5.19±0.96	2.95–7.90	5.34±0.83	5.05±1.06	0.140
Total triglycerides (mmol/l)	1.60±1.36	0.40–9.92	1.90±1.69	1.31±0.82	0.034
Glucose (mmol/l)	6.76±2.65	4.38–22.84	8.31±2.91	5.22±0.92	0.000
ALT (IU/l)	21.5±15.9	5.0–99.0	25.1±18.5	18.0±12.1	0.028
Uric acid (μmol/l)	294.9±81.1	132.0–531.0	289.3±70.5	300.6±90.9	0.499
CALM2 methylation (%)
CpG1	0.96±0.38	0–2	1.02±0.40	0.88±0.33	0.099
CpG2	2.01±0.50	0–3	2.18±0.39	1.79±0.55	0.001
CpG3	0.92±0.48	0–2	1.00±0.53	0.82±0.39	0.087
CpG4	1.40±0.86	0–5	1.11±0.58	1.79±1.02	0.001
CRY2 methylation (%)
CpG1	1.25±0.53	0–2	1.13±0.41	1.44±0.65	0.022
CpG2	0.80±0.41	0–1	0.79±0.41	0.80±0.41	0.961
CpG3	1.61±0.63	0–3	1.64±0.63	1.56±0.65	0.621
CpG4	0.98±0.42	0–3	1.05±0.39	0.88±0.44	0.110
CpG5	1.14±3.32	0–27	0.64±0.54	1.92±5.24	0.134
CAMK1D methylation (%)
CpG1	1.04±0.29	0–3	1.04±0.20	1.04±0.36	1.000
CpG2	0.75±0.48	0–2	0.90±0.31	0.60±0.57	0.003
CpG3	1.53±0.54	1–3	1.75±0.48	1.31±0.51	0.000
CpG4	1.04±0.29	0–2	1.10±0.31	0.98±0.25	0.032
CpG5	1.02±0.20	0–2	1.04±0.20	1.00±0.21	0.320
CpG6	0.96±0.32	0–2	1.02±0.14	0.90±0.43	0.057
CpG7	1.04±0.29	0–2	1.06±0.38	1.02±0.14	0.480
CpG8	0.92±0.45	0–3	1.02±0.25	0.81±0.57	0.023
CpG9	0.82±0.54	0–3	1.00±0.41	0.65±0.60	0.001

Results are expressed as the mean ± standard error.

^an=86 (46 patients with T2D vs. 40 control patients).

T2D, type 2 diabetes; BMI, body mass index; ALT, alanine aminotransferase; CALM2, calmodulin 2; CRY2, cryptochrome 2; CAMK1D, calcium/calmodulin-dependent protein kinase 1D; M, male; F, female.